Advancing Rare Disease Therapies Across the Finish Line
Drug development is a marathon, often taking years to complete. This is especially true in rare disease, where the development path is rarely linear.
Unfortunately, this process sometimes requires a relay, as corporate strategy shifts result in programs getting deprioritized mid-way through development.
Oak Hill was founded to take the baton where others left off - acquiring and developing deprioritized late-stage rare disease drugs and bringing them across the finish line.
Transforming Discoveries
Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing rare disease drugs that have been deprioritized by big pharma. Our pipeline includes two late-stage therapeutic candidates: rugonersen (OHB-724), an antisense oligonucleotide (ASO) for Angelman syndrome, and mecasermin rinfabate (OHB-607), recombinant human IGF-1/IGFBP-3, for complications of extremely premature birth.
In The Press
